Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TISA-818
- Development stage
- Phase 2
- Lead developer
- EnliTISA
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
TISA-818 is a first-in-class small molecule investigational drug developed by EnliTISA for the treatment of acute respiratory distress syndrome (ARDS). It possesses a novel molecular structure and a unique mechanism of action characterized as an immune-sparing anti-inflammatory. This approach suppresses excessive inflammation while preserving essential immune responses and modulating the resolution of inflammation. TISA-818 is administered via intravenous injection for ARDS, and a subcutaneous formulation is under development for idiopathic pulmonary fibrosis (IPF). A Phase II clinical trial for ARDS in China was completed in early 2025.
Beyond the preview
Go deeper on TISA-818.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TISA-818.